Bearishness Around Pfizer Gilead Sparks Opportunity
Wall Street traders weigh a contrarian opportunity as Pfizer and Gilead trade below fair value amid rising bearish se...
Pfizer
This Pfizer tag page curates 3 articles examining stock potential, key risks, and long-term strategies. It helps you assess impact on your finances and make informed moves.
32 articles
Pfizer Amgen: That Pfizer’s Seagen Bet Could Lead
Pfizer’s Seagen integration is starting to pay off, signaling a shift in oncology bets as Amgen pursues a rebuild thr...
Pfizer Highest-Yielding Dividend 500: Risk or Reward?
Pfizer currently draws attention for its high dividend yield, but a big payout can mask risk. This guide explains how...
Abbott Labs Pfizer: Which Is the Bigger Value Trap Now
Abbott Laboratories and Pfizer both delivered solid Q1 2026 numbers, yet the market sentiment diverged. Abbott slumpe...
McDonald’s Beats Pfizer on Growth; Investors Watch Now
As mid-2026 trading picks up, McDonald’s demonstrates stronger growth and cash flow versus Pfizer, which relies on in...
It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Opinion: Pfizer's Dividend Riskier Than It Looks, Even with a 7% Yield
Pfizer’s high dividend yield is eye-catching, but a big payout can hide hidden risks. This article explains the warni...
Pfizer's Says Company "Very" Big Balance Sheet for Deals
Pfizer signals it can bankroll ambitious deals with a robust balance sheet. This article weighs what a 'very big' bal...
Pfizer Verizon Communications: Which High-Yield Stock Wins
Dividend investors face a crowded field. This article compares Pfizer and Verizon Communications to answer pfizer ver...
Pfizer Could Prove Underrated GLP-1 Stock Opportunity
Pfizer may be sitting on a hidden GLP-1 opportunity. This article breaks down why the company could prove to be an un...
Departure. Clinical Miss. Billion: Should You Bet on Pfizer?
Pfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
Lilly vs Pfizer: Obesity Race Reaches Market Highs
Lilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...